Category: Zacks Small Cap Research

1237610 / 760 POSTS
By John Vandermosten, CFANASDAQ:PHIOREAD THE FULL PHIO RESEARCH REPORT Full Year 2019 Financial & Operational Update Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported full year 2019 results and filed its Form 10-K on March 26, 2020. The prior yea ...
By John Vandermosten, CFATSX:PMN.TO | OTC:ARFXFREAD THE FULL PMN.TO RESEARCH REPORT Full Year 2019 Operational and Financial Results 2019 provided a wild ride in the β-amyloid (βA) space. In March 2019, Biogen (NASDAQ:BIIB) announced that its Phase ...
By John Vandermosten, CFATSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Second Quarter 2019 Operational and Financial Results Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported second quarter 2020 results and submitted its SEDAR fi ...
By John Vandermosten, CFANASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2019 Operational and Financial Results On March 13, 2020 Lipocine (NASDAQ:LPCN) filed its fiscal year 2019 10-K and posted its earnings release for the twelve-month period ending ...
By John Vandermosten, CFANASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Fourth Quarter and Full Year 2019 Review Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported fourth quarter and full year results in a press release and conference call held on Ma ...
By Ann Heffron, CFA, CPAOTC:CPKF READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial’s (OTC:CPKF) fourth quarter net earnings rose $61,000, or 3%, year over year to $1.9 million, while 2019’s fourth quarter diluted EPS increased by $0.02, or 3%, ...
By David Bautz, PhDNASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Interim Analysis of Phase 3 RELIEF Trial in 3Q20 In December 2019, Tonix Pharmaceutical Holding Corp. (NASDAQ:TNXP) announced the first participant enrolled into the Ph ...
By David Bautz, PhDNASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating TSC as Treatment for ARDS On April 1, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company will be evaluating its lead development ...
By David Bautz, PhDNASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT We are initiating coverage of Edesa Biotech, Inc. (NASDAQ:EDSA) with a valuation of $5.00. Edesa is a biopharmaceutical company focused on developing therapies for dermatological and g ...
By David Bautz, PhDNASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT IND for EPI-7386 Filed On March 31, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) announced that it submitted an Investigation New Drug (IND) application for EPI-7386, the company’s lead clinic ...
1237610 / 760 POSTS